The USA pays substantially more for the same branded drug compared with other high-income nations, with estimates suggesting the USA pays three to five times the price compared with most European countries.1 For many, including the Trump administration, these higher prices represent an unfairness in the global pharmaceutical market. In his first term, US President Donald Trump directed the Centers for Medicare and Medicaid Innovation (CMMI) to benchmark Medicare part B drug prices to international prices as a form of international reference pricing.
Kaynak: The Lancet
